Intragastric Balloon Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||1005958|
|出版日期||內容資訊||英文 119 Pages
|胃水球的全球市場:成長，趨勢，COVID-19的影響，預測(2021年∼2026年) Intragastric Balloon Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)|
|出版日期: 2021年04月21日||內容資訊: 英文 119 Pages||
COVID-19 有可能對胃球囊市場產生重大影響。在 COVID-19 大流行期間，患有肥胖症等潛在疾病的人面臨更高的風險。根據美國疾病控制與預防中心 2021 年 3 月發布的數據，估計所有 COVID-19 住院治療中約有 30.2% 是由肥胖引起的。
還有肥胖在 COVID-19 情況下呈指數增長。根據 2020 年 12 月發表在《歐洲營養學雜誌》上的一篇文章，全球肥胖率正在上升。主要原因是人們由於社交距離協議而避免去健身房和瑜伽課，因此生活方式的改變和運動量的減少。肥胖人口的增加預計將在不久的將來增加對胃氣球的需求。
The intragastric balloon market is expected to grow with a CAGR of 9% during the forecast period.
COVID-19 is likely to have a profound impact on the intragastric balloon market. People with an underlying condition such as obesity are at even greater risk during the COVID-19 pandemic. As per the data published by the Center for Disease Control and Prevention in March 2021, estimated that around 30.2% of total COVID-19 hospitalizations were attributed to obesity.
Also, it has been observed that during the COVID-19 situation the obesity had increased exponentially. As per an article published by the European Journal of Nutrition in December 2020, the rate of obesity has increased in the world. The major reason being a change in lifestyle and a decrease in exercise practice among people as they avoided gym and yoga classes due to the social distancing protocols. This increase in the obesity population is expected to drive the demand for intragastric balloons in the near future.
Other key factors attributing to the rising adoption of minimally invasive treatment and the increasing prevalence of obesity. For instance, as per the data published by World Health Organization in 2020, more than 1.9 billion adults, 18 years and older, were overweight, of these over 650 million were obese. Intragastric balloons are used in the treatment of obesity by placing the device temporarily in the stomach. This device helps the person in reducing weight by making them eat less. With the high prevalence of obesity worldwide and increasing adoption of weight loss surgery like sleeve gastrectomy and gastric bypass leading to high mortality due to obesity. This will surge the demand for alternative procedures and minimally invasive procedures such as an intragastric balloon.
However, side effects or complications associated with intragastric balloons may hamper market growth.
Single Intragastric Balloon Market is Estimated to Witness a Healthy Growth in Future.
Single Intragastric balloon is estimated to witness healthy growth in the future which is attributed to increasing awareness, rising demand for minimally invasive procedures, availability of a large number of products in the market, and scientific proofs for their safety and efficacy. As per the National Institute of Health (NIH), a report was published in 2018, which said that the Orbera intragastric balloon, a type of single fluid-filled intragastric balloon is safe and effective for reducing obesity-related comorbidities in a real-world population and weight loss population.
The epidemic of obesity is impacting the severity of the COVID-19 pandemic. As per the data published by the Center of Disease Control and Prevention in 2021, obesity may triple the risk of hospitalization due to a COVID-19 infection and it is linked to impaired immune function. Additionally, it decreases lung capacity and reserve and can make ventilation more difficult. Thus, benefits offered by the existing single balloon system, such as minimal downtime and fully reversible treatment, are anticipated to increase the demand for this type of intragastric balloon during the upcoming period.
Moreover, increasing the number of obese patients with several technological advancements for better outcomes and developments in the intragastric balloon will also promote segment growth in the future. Factors such as the rising intake of junk foods/fast foods are resulting in declining health among the population worldwide, leading to an increase in the prevalence of obesity, especially in some developed parts of the world, which is also likely to fuel the vertical growth. For instance, in the United States, from 1999-2000 and 2017-2018, the prevalence of obesity increased from 30.5% to 42.4%, and the prevalence of severe obesity increased from 4.7% to 9.2%, as per the 2018 report by the Centers for Disease Control and Prevention. The obesity is expected to continue increasing over the forecast period, thus fueling the segmental growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Intragastric Balloon Market due to the increasing obese population and high adoption of weight loss treatments. As per data provided by Organisation for Economic Co-operation and Development (OECD), in 2017, around 38.2% of the United State Population was obese and it is the highest in the World.
Also, as per the data published by the Organization for Economic Co-operation and Development, in Canada, 59.1% of the population aged 15 years or more were obese, whereas, in Mexico, 75.2% of the population aged 15 years or more was obese in 2017- 2018.
This is resulting in high demand for the minimally invasive procedure and as the population in this region are more inclined in adopting new innovations results in propelling the market growth in this region. Moreover, favorable regulatory scenarios, healthcare expenditure, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
As the pandemic has impacted the business and quality of life of the population across the country, the treatment of most of them have been postponed, unless it is an emergency. However, this would also impact the couples who are in the midst of obesity treatments.
The Intragastric balloon market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Obalon Therapeutics, Apollo Endosurgery, Inc., Allurion Technologies Inc, Spatz3, ReShape Lifesciences, MEDSIL, Helioscopie and Silimed. Mergers and acquisition, divestments, and new product development and launch are the key strategies adopted by the established market players while some emerging players are involved in obtaining funding for their product development and lunch.